Company
Every investor coverage indicates participated in a round Shire raised.
Every published round Shire took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Shire has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Shire, as distinct from the investments it has made.
Companies Shire has backed that another company then bought. An exit for the holding, not a deal Shire did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| No portfolio company of Shire is recorded as having been acquired. | ||||
The transaction that ended Shire's run as a startup, per published coverage. It closes the funding history too, where it is the ladder's last rung.
| Bought by | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Takeda | Acquisition | 2018 | - | Brandon BioCatalyst, Brandon Capital |
Companies Shire acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Company | Kind | Announced | Price | Sources |
|---|---|---|---|---|
| Fibrotech | Acquisition | 2014 | - | Brandon BioCatalyst, Brandon Capital |
Stories naming Shire. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.